Search results for "Guidelines as Topic"

showing 10 items of 372 documents

New horizons in early stage COPD--improving knowledge, detection and treatment.

2011

SummaryEarly stage COPD carries a significant healthcare burden that is currently underrecognised, underdiagnosed and undertreated. Furthermore, patients at this stage can rapidly decline to advanced disease, especially if they continue to smoke. The natural history of the disease in early stages remains largely unknown, and emerging evidence indicates that we are able to reduce lung function decline and exacerbations, and improve quality of life, in early stage COPD, mainly through smoking cessation. But new evidence from randomised clinical trials also suggests an impact of pharmacotherapy on clinical outcomes in early disease. Guidelines need to be updated to reflect this greater underst…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentDiseasePulmonary Disease Chronic ObstructiveQuality of life (healthcare)PharmacotherapyHealth careDiagnosismedicineCOPDHumansIntensive care medicineCOPDbusiness.industryCase-findingEarly diseasemedicine.diseasePrognosisBronchodilator AgentsClinical trialNatural historyTreatmentEarly DiagnosisSpirometryPractice Guidelines as TopicPhysical therapyQuality of LifeSmoking cessationFemaleSmoking CessationbusinessRespiratory medicine
researchProduct

Two pathways, one patient; UK asthma guidelines

2018

The first widely disseminated ‘asthma guideline’ came out of Australia and New Zealand in 1989,1 followed shortly by the British Thoracic Society (BTS) in 1990,2 the United States National Heart, Lung, and Blood Institute Expert Panel Report in 19913 and the Global Initiative for Asthma (GINA) strategy document in 1995.4 All have benefited from regular updates, the BTS collaborating with the Scottish Intercollegiate Guideline Network (SIGN) since 2003, most recently in 2016.5 Each new iteration of the asthma guidelines was written by experts in the field and based on best available evidence. It is not known whether these guidelines (or any others) have improved the care of people with asthm…

Pulmonary and Respiratory MedicinePopulation ageingmedicine.medical_specialtymedia_common.quotation_subjectComplex diseaseNice03 medical and health sciences0302 clinical medicineExcellenceHumansMedicine030212 general & internal medicinecomputer.programming_languagemedia_commonAsthmaHealth economicsbusiness.industryGuidelinemedicine.diseaseAsthmaUnited KingdomFalling (accident)030228 respiratory systemFamily medicinePractice Guidelines as Topicmedicine.symptombusinesscomputerThorax
researchProduct

Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement

2015

Background Exacerbations are a key outcome in clinical research, providing patient-relevant information about symptomatic control, health state and disease progression. Generally considered as an episode of (sub)acute deterioration of respiratory symptoms, a precise, clinically useful definition is needed for use in clinical trials. Aim and methods Focussing on moderate exacerbations, this opinion piece reviews landmark trials and current guidelines to provide a practical definition of a moderate exacerbation. Specifically, we adapt the ATS/ERS consensus statement of terminology Reddel et al. (2009) [1] which provides a conceptual (or 'theoretical') definition for moderate exacerbations, to…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationStatement (logic)Moderate asthmaSeverity of Illness IndexAdrenal Cortex HormonesAsthma controlAdministration InhalationmedicineHumansModerate exacerbationsAnti-Asthmatic AgentsBaseline (configuration management)Randomized Controlled Trials as TopicAsthmaOperational definitionbusiness.industrymedicine.diseaseAsthmaClinical trialClinical trialClinical researchPractice Guidelines as TopicDisease ProgressionPhysical therapyEmergency Service HospitalbusinessRespiratory Medicine
researchProduct

Contemporary spinal cord protection during thoracic and thoracoabdominal aortic surgery and endovascular aortic repair: a position paper of the vascu…

2015

Ischaemic spinal cord injury (SCI) remains the Achilles heel of open and endovascular descending thoracic and thoracoabdominal repair. Neurological outcomes have improved coincidentially with the introduction of neuroprotective measures. However, SCI (paraplegia and paraparesis) remains the most devastating complication. The aim of this position paper is to provide physicians with broad information regarding spinal cord blood supply, to share strategies for shortening intraprocedural spinal cord ischaemia and to increase spinal cord tolerance to transitory ischaemia through detection of ischaemia and augmentation of spinal cord blood perfusion. This study is meant to support physicians cari…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyHeelIntraoperative Neurophysiological MonitoringIschemiaThoracic Surgical ProcedureAorta Thoracic610 Medicine & healthSpinal cord injuryThoracic aorta142-005 142-0052705 Cardiology and Cardiovascular Medicinemedicine.arterymedicineThoracic aortaHumansAorta Abdominal610 Medicine & healthSpinal cord injuryEndovascular ProcedureAortic Aneurysm ThoracicTEVARbusiness.industrySpinal Cord IschemiaEndovascular ProceduresThoracoabdominal aortaGeneral MedicineThoracic Surgical Proceduresmedicine.diseaseSpinal cordSurgery2746 SurgeryEuropemedicine.anatomical_structureSpinal CordCardiothoracic surgery2740 Pulmonary and Respiratory MedicineAnesthesiaPractice Guidelines as TopicSurgeryParaplegiaComplicationbusinessCardiology and Cardiovascular MedicineHuman
researchProduct

Sublingual immunotherapy in children.

2018

Pulmonary and Respiratory Medicinemedicine.medical_specialtyImmunology03 medical and health sciences0302 clinical medicine030225 pediatricsImmune ToleranceImmunology and AllergyMedicineAnimalsHumansSublingual immunotherapy030212 general & internal medicineAntigens DermatophagoidesChildClinical Trials as TopicSublingual ImmunotherapyDermatophagoides farinaebusiness.industryGeneral MedicineDermatologyRhinitis AllergicAsthmaChild PreschoolPractice Guidelines as TopicbusinessAllergologia et immunopathologia
researchProduct

Asthma diagnosis in infants and preschool children: a systematic review of clinical guidelines.

2019

Background and aim: The definition and diagnosis of asthma are the subject of controversy that is particularly intense in the case of individuals in the first years of life, due to reasons such as the difficulty of performing objective pulmonary function tests or the high frequency with which the symptoms subside in the course of childhood. Since there is no consensus regarding the diagnosis of asthma in preschool children, a systematic review has been carried out. Materials and methods: A systematic search was made of the clinical guidelines published in the last 10 years and containing information referred to the concept or diagnosis of asthma in childhood - including the first years of l…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyImmunologyPulmonary function testingHumansImmunology and AllergyMedicineAnti-Asthmatic AgentsMedical diagnosisChildAsthmaAsthma Diagnosis Guidelines Infants Preschool children Systematic reviewProtocol (science)business.industryInfantGeneral Medicinemedicine.diseaseResponse to treatmentAsthmaRespiratory Function TestsSystematic reviewSpainChild PreschoolFamily medicinePractice Guidelines as TopicbusinessSystematic search
researchProduct

Care pathways for the selection of a biologic in severe asthma.

2017

Physicians need care pathways to select a biologic in type 2 severe asthma (omalizumab, mepolizumab, reslizumab) http://ow.ly/pygw30gB7Bv

Pulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaMEDLINEmacromolecular substancesOmalizumab03 medical and health sciences0302 clinical medicineReslizumabmedicineHumans030212 general & internal medicineIntensive care medicineSelection (genetic algorithm)Randomized Controlled Trials as TopicAsthma therapyBiological Productsbusiness.industryAntibodies MonoclonalAsthma030228 respiratory systemPractice Guidelines as TopicCritical PathwaysbusinessMepolizumabmedicine.drugThe European respiratory journal
researchProduct

Severe asthma and COVID-19: lessons from the first wave

2020

Objective: Severe asthma is considered a risk factor for SARS-Coronavirus 2 (SARS-CoV-2) infection but scientific evidences are lacking. Methods: we performed a literature search and review based on PubMed database national, international recommendations as well as papers on severe asthmatic patients and their management during SARS-CoV-2 pandemic. Results: the majority of international recommendations, expert panels and editorials provide indications about management of severe asthmatic patients. No published studies evaluated the effects of biologic agents on severe asthmatic patients during SARS-CoV-2 pandemic. Conclusions: the relationship between SARS-CoV-2 and asthma is variable world…

Pulmonary and Respiratory Medicinesevere asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)biologic agentsvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaInhaled corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroids03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsPediatrics Perinatology and Child Health030212 general & internal medicineRisk factorskin and connective tissue diseasesPandemicsAsthmabusiness.industryAsthma; biologic agents; COVID-19; inhaled corticosteroids; oral corticosteroids; SARS-CoV-2; severe asthmaSARS-CoV-2fungiPatient AcuityAsthma biologic agents COVID-19 inhaled corticosteroids oral corticosteroids SARS-CoV-2 severe asthmaCOVID-19medicine.diseaseAsthmarespiratory tract diseasesBiologic Agentsbody regions030228 respiratory systemPractice Guidelines as TopicPediatrics Perinatology and Child Healthinhaled corticosteroidsbusiness
researchProduct

[Clinical guidelines for the management of gastrointestinal stromal tumors]

2006

Treatment of gastrointestinal stromal tumors (GIST) has been revolutioned by the recently discovered molecular mechanism responsible for the oncogenesis of this disease. In addition, due to the rapid progress at molecular and clinical level observed in the last few years, there is a need to review the current state of the art in order to delineate appropriate guidelines for the optimal management of these tumors. A panel of experts from several specialities, including medical oncology, surgery, pathology, molecular biology and imaging, were invited to participate in a meeting to present and discuss a number of pre-selected questions, and to achieve a consensus according to the categories of…

PyrimidinesGastrointestinal Stromal TumorsBenzamidesDecision TreesPractice Guidelines as TopicDisease ProgressionImatinib MesylateHumansAntineoplastic AgentsNeoplasm Recurrence LocalCombined Modality TherapyPiperazines
researchProduct

The role of the reporting framework MIATA within current efforts to advance immune monitoring

2014

Quality Controlmedicine.medical_specialtyLaboratory Proficiency TestingConsensusmedicine.medical_treatmentInternational CooperationT-LymphocytesImmunologyImmune monitoringPharmacologyImmunologic TestsImmune assaysMonitoring ImmunologicPredictive Value of TestsmedicineImmunology and AllergyHumansCooperative BehaviorIntensive care medicineImmune monitoringObserver Variationbusiness.industryGuideline adherenceMIATAImmunologic TestsReproducibility of ResultsImmunotherapyTreatment OutcomeReportingPredictive value of testsPractice Guidelines as TopicCooperative behaviorLaboratory Proficiency TestingGuideline AdherenceImmunotherapyCurrent (fluid)businessLaboratories
researchProduct